Litcius/Paper detail

Potential benefit of the cathepsin S inhibitor, ASP1617, as a treatment for systemic lupus erythematosus

Yuka Kawato, Hidehiko Fukahori, Koji Nakamura, Atsuo Kanno, Kaori Kubo, Masaki Hiramitsu, Toshihiro Matsuda, Yuichi Hanada, Takako Furukawa, Yutaka Nakajima, Fumitaka Kinugasa, Tatsuaki Morokata

2022European Journal of Pharmacology10 citationsDOI

Topics & Concepts

ImmunologyAutoantibodyAntigenAntigen presentationLupus nephritisSystemic lupus erythematosusMHC class IIMajor histocompatibility complexPathogenesisAutoimmune diseaseAutoimmunityBiologyMedicineT cellAntibodyImmune systemInternal medicineDiseaseSystemic Lupus Erythematosus ResearchT-cell and B-cell ImmunologyMonoclonal and Polyclonal Antibodies Research
Potential benefit of the cathepsin S inhibitor, ASP1617, as a treatment for systemic lupus erythematosus | Litcius